Replay available

Avalo Therapeutics, Inc. (AVTX) Q4 2023 Earnings Call

Avalo Therapeutics, Inc. (NASDAQ: AVTX) Q4 2023 earnings conference call, held 2024-02-28. Replay captured from the company's public earnings webcast.

Wed, February 28, 2024 at 9:00 AMendedReplay
Avalo Therapeutics, Inc. (AVTX) Q4 2023 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Megan Bacon

Director of Investor Relations

Rob Pomeroy

Chairman and Chief Executive Officer

Dan Dvoracic

Chief Operating Officer and Chief Investment Officer

Jerry Michaud

President

Dan Trollio

Chief Financial Officer

Bryce Rowe

Analyst, B. Riley Securities

Paul Johnson

Analyst, KBW

Replay transcript excerpt

Greetings and welcome to the Horizon Technology Finance Corporation fourth quarter 2023 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Megan Bacon, Director of IR. Thank you, and welcome to Horizon Technology Finance Corporation's fourth quarter 2023 conference call. Representing the company today are Rob Pomeroy, Chairman and Chief Executive Officer, Jerry Michaud, President, Dan Dvoracic, Chief Operating Officer and Chief Investment Officer, and Dan Trollio, Chief Financial Officer. I would like to point out that the Q4 earnings press release and Form 10-K are available on the company's website at horizontechfinance.com. Before we begin our formal remarks, I need to remind everyone that during this conference call, the company will make certain forward-looking statements, including statements with regard to the future performance of the company. Words such as believe, expect, anticipate, Intense or similar expressions are used to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors could cause actual results to differ on a material basis from those projected in these forward-looking statements. And some of these factors are detailed in the risk factor discussion in the company's filings with the Securities and Exchange Commission including the company's Form 10-K for the year ended December 31, 2023. The company undertakes no obligati...

More from Avalo Therapeutics, Inc.